Ketamine treatment for depression: a review

This manuscript reviews the clinical evidence regarding single-dose intravenous (IV) administration of the novel glutamatergic modulator racemic (R,S)-ketamine (hereafter referred to as ketamine) as well as its S-enantiomer, intranasal esketamine, for the treatment of major depressive disorder (MDD)...

Descripción completa

Detalles Bibliográficos
Autores principales: Yavi, Mani, Lee, Holim, Henter, Ioline D., Park, Lawrence T., Zarate, Carlos A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9010394/
https://www.ncbi.nlm.nih.gov/pubmed/35509843
http://dx.doi.org/10.1007/s44192-022-00012-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9010394/
https://www.ncbi.nlm.nih.gov/pubmed/35509843
http://dx.doi.org/10.1007/s44192-022-00012-3

Ejemplares similares